The launch arrives at a pivotal moment as several high-cost cancer therapies approach their loss of exclusivity. Despite the presence of biosimilar competition, market pricing remains unpredictable, often fluctuating quarter to quarter and preventing meaningful savings from reaching patients. Thyme Therapeutics intends to bridge this gap by facilitating broader adoption of lower-cost, clinically appropriate treatments.
Thyme Companies Targets Oncology Drug Costs With New Biosimilar Venture
With U.S. oncology drug spending surging to $84 billion in 2025, a 20% annual increase, Nashville-based Thyme Companies has launched Thyme Therapeutics. The new venture aims to stabilize the volatile pricing of cancer biosimilars by aligning incentives between manufacturers, health plans, and oncology providers ahead of critical exclusivity expirations.
Robin Shah, executive chairman of Thyme Companies, identified the rising cost of cancer care as one of the industry's most urgent challenges. The new entity plans to debut its first asset in 2027, leveraging the infrastructure of its parent organization, which recently secured Series E financing in September 2026. By working directly with oncologists and payers, the firm seeks to transform the economic framework of cancer treatment, ensuring that cost reductions are both durable and predictable for the healthcare system.
Comments (0)
No comments yet. Be the first!